Literature DB >> 23324958

Bacteriophage therapy in implant-related infections: an experimental study.

Cengiz Yilmaz1, Mehmet Colak, Banu Coskun Yilmaz, Gulden Ersoz, Mzia Kutateladze, Mehmet Gozlugol.   

Abstract

BACKGROUND: Implant-related infections with bacteria resistant to multiple antibiotics represent one of the major problems in orthopaedic surgery. It was our hypothesis that local application of bacteriophages, which are bacteria-destroying viruses, would be effective against biofilm-forming bacteria.
METHODS: An implant-related infection model was created using methicillin-resistant Staphylococcus aureus (MRSA) in forty-eight rats and Pseudomonas aeruginosa in another forty-eight rats. Each group was divided into four subgroups; one subgroup received a bacterium-specific bacteriophage (Sb-1 in the MRSA group and PAT14 in the Pseudomonas aeruginosa group), one received antibiotic for fourteen days (20 mg/kg/day teicoplanin in the MRSA group, and 120 mg/kg/day imipenem + cilastatin and 25 mg/kg/day amikacin in the Pseudomonas group), one received antibiotic and bacteriophage, and one received no treatment. Animals receiving bacteriophage therapy were injected locally with 107 bacteriophages in a 0.1-mL suspension on three consecutive days. All animals were killed on the fifteenth day after initiation of treatment, and the tibia was excised. Results were assessed with use of microbiology, light microscopy, and electron microscopy.
RESULTS: In the MRSA group, the antibiotic administration significantly decreased the number of colony-forming units per subject in quantitative cultures (control subgroup, 50,586; bacteriophage, 30,788; antibiotic, 17,165; antibiotic + bacteriophage, 5000; p = 0.004 for the comparison of the latter group with the control). Biofilm was absent only in the antibiotic + bacteriophage subgroup. In the Pseudomonas group, the number of colony-forming units per subject in quantitative cultures was significantly lower in each treatment subgroup compared with the control subgroup (control subgroup, 14,749; bacteriophage, 6484 [p = 0.016]; antibiotic, 2619 [p = 0.01]; antibiotic + bacteriophage, 1705 [p < 0.001]). The value in the antibiotic + bacteriophage subgroup was also significantly lower than the values in the other subgroups (p = 0.006). Biofilm thickness did not differ significantly among the subgroups in the Pseudomonas group.
CONCLUSIONS: The addition of bacteriophage treatment to an appropriate antibiotic regimen helped to dissolve the biofilm of both types of bacteria studied. This effect on MRSA was more pronounced than that on Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23324958     DOI: 10.2106/JBJS.K.01135

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  53 in total

1.  Targeting Enterococcus faecalis biofilms with phage therapy.

Authors:  Leron Khalifa; Yair Brosh; Daniel Gelman; Shunit Coppenhagen-Glazer; Shaul Beyth; Ronit Poradosu-Cohen; Yok-Ai Que; Nurit Beyth; Ronen Hazan
Journal:  Appl Environ Microbiol       Date:  2015-02-06       Impact factor: 4.792

2.  Evaluation of the Activity of a Combination of Three Bacteriophages Alone or in Association with Antibiotics on Staphylococcus aureus Embedded in Biofilm or Internalized in Osteoblasts.

Authors:  Camille Kolenda; Jérôme Josse; Mathieu Medina; Cindy Fevre; Sébastien Lustig; Tristan Ferry; Frédéric Laurent
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 3.  Using viruses as nanomedicines.

Authors:  H E van Kan-Davelaar; J C M van Hest; J J L M Cornelissen; M S T Koay
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

4.  Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo.

Authors:  James A Wroe; Christopher T Johnson; Andrés J García
Journal:  J Biomed Mater Res A       Date:  2019-09-05       Impact factor: 4.396

Review 5.  Engineering microbes for targeted strikes against human pathogens.

Authors:  In Young Hwang; Hui Ling Lee; James Guoxian Huang; Yvonne Yijuan Lim; Wen Shan Yew; Yung Seng Lee; Matthew Wook Chang
Journal:  Cell Mol Life Sci       Date:  2018-05-07       Impact factor: 9.261

Review 6.  Bacteriophages and Lysins in Biofilm Control.

Authors:  Marzanna Łusiak-Szelachowska; Beata Weber-Dąbrowska; Andrzej Górski
Journal:  Virol Sin       Date:  2020-03-03       Impact factor: 4.327

Review 7.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

Review 8.  Therapeutics and delivery vehicles for local treatment of osteomyelitis.

Authors:  Leah H Cobb; Emily M McCabe; Lauren B Priddy
Journal:  J Orthop Res       Date:  2020-04-21       Impact factor: 3.494

Review 9.  The role of biofilm on orthopaedic implants: the "Holy Grail" of post-traumatic infection management?

Authors:  C Mauffrey; B Herbert; H Young; M L Wilson; M Hake; P F Stahel
Journal:  Eur J Trauma Emerg Surg       Date:  2016-06-04       Impact factor: 3.693

10.  Correlation of Host Range Expansion of Therapeutic Bacteriophage Sb-1 with Allele State at a Hypervariable Repeat Locus.

Authors:  Kirill V Sergueev; Andrey A Filippov; Jason Farlow; Wanwen Su; Leila Kvachadze; Nana Balarjishvili; Mzia Kutateladze; Mikeljon P Nikolich
Journal:  Appl Environ Microbiol       Date:  2019-10-30       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.